Trabectedin Accord

Trabectedin Accord is a cancer medicine used to treat adults with: - soft-tissue sarcoma, a type of cancer that develops from the soft, supporting tissues of the body. Trabectedin Accord is used in patients whose cancer is advanced (has started spreading) when anthracyclines and ifosfamide (other cancer medicines) have stopped working or when patients cannot take these medicines; - ovarian cancer (cancer of the ovaries) that has relapsed (come back after previous treatment) and is responding to platinum-based chemotherapy. In these patients, Trabectedin Accord is used in combination with pegylated liposomal doxorubicin (PLD, another cancer medicine). Trabectedin Accord contains the active substance trabectedin and is a ‘generic medicine’. This means that Trabectedin Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Trabectedin Accord is Yondelis. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf).